SCHEMBL6525014

SCHEMBL6525014

CN1CCCC1CCNc1ccc2c(=O)[nH]c3ncccc3c2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 2/20 0.59
NPC1 O15118 1/20 0.58
RAB9A P51151 1/20 0.58
ERAP1 Q9NZ08 1/20 0.58
GFER P55789 1/20 0.52
MITF O75030 1/20 0.52
UHRF1 Q96T88 1/20 0.50
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
AURKA O14965 1/20 0.44
PARP1 P09874 1/20 0.44
TERT O14746 1/20 0.44
HRH2 P25021 1/20 0.42
HRH1 P35367 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
CAMK2D Q13557 1/20 0.41
ACP1 P24666 2/20 0.41
GABRP O00591 1/20 0.41
GABRD O14764 1/20 0.41
GABRA1 P14867 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6523008 0.80 PARP1 (0.51) AURKAPARP1HRH3KAT2B
SCHEMBL6533053 0.77 AURKA (0.54) MEN1KMT2AAURKAPARP1
SCHEMBL6517410 0.76 ALDH1A1 (0.51) NPC1RAB9AGFERMEN1KMT2A
SCHEMBL6522568 0.76 PARP1 (0.46) GFERMEN1KMT2AAURKAPARP1
SCHEMBL6525635 0.72 AURKA (0.56) NPC1RAB9AAURKAPARP1HRH3
SCHEMBL6517375 0.71 AURKA (0.51) NPC1RAB9AAURKAPARP1
SCHEMBL3454371 0.70 AURKA (0.60) AURKAPARP1CAMK2DGABRPGABRD
SCHEMBL6525846 0.70 AURKA (0.47) MEN1KMT2AAURKAPARP1GABRP
SCHEMBL6521479 0.70 CDK2 (0.50) NPC1RAB9AMEN1KMT2AAURKA
SCHEMBL6521930 0.70 PARP1 (0.52) KMT2AAURKAPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
WO-2009108670-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 RAD52 4082/4885NPC1 3403/4885RAB9A 1390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.